← back to search

Gang Zhou

Augusta University Health · US
Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and Immune cells in cancer.
h-index
37
citations
6,057
works
133
NIH funding
primary concept
Medicine
email

Recent publications

Cyclic nucleotide phosphodiesterases as drug targets
Pharmacological Reviews 2025cited by 22position: middledoi
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
2025cited by 19position: contributordoi
Cyclic nucleotide phosphodiesterases as drug targets.
2025cited by 14position: contributordoi
β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy.
2025cited by 2position: contributordoi
Abstract 4391: A novel dual inhibitor of RAS and β-catenin signaling with advantages over mutant-specific KRAS inhibitors to escape resistance has robust antitumor efficacy and activates antitumor immunity
Cancer Research 2025cited by 0position: lastdoi
Targeting phosphodiesterase 10 unleashes antitumor immunity by inhibiting the RAS-MAPK signaling in cancer cells and myeloid-derived suppressor cells 3553
The Journal of Immunology 2025cited by 0position: lastdoi
Calcium nanoparticles target and activate T cells to enhance anti-tumor function
Nature Communications 2024cited by 23position: middledoi
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Cancer Research 2024cited by 21position: middledoi
Calcium nanoparticles target and activate T cells to enhance anti-tumor function.
2024cited by 19position: contributordoi
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription
Anti-Cancer Agents in Medicinal Chemistry 2024cited by 3position: middledoi
Abstract 2459: ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity
Cancer Research 2024cited by 0position: lastdoi
1649P Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Annals of Oncology 2024cited by 0position: middledoi
Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity
Cancer Insight 2023cited by 2position: middledoi
Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity
Cancer Insight 2023cited by 1position: middledoi
Abstract 1633: ADT-030, a novel dual-acting RAS and β-catenin inhibitor with robust antitumor activity
Cancer Research 2023cited by 0position: middledoi
Abstract 478: A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy
Cancer Research 2023cited by 0position: lastdoi
Abstract 6333: Repurposing NSAIDs for chemo-immunotherapy: mechanisms beyond COX inhibition
Cancer Research 2023cited by 0position: lastdoi
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy
Journal for ImmunoTherapy of Cancer 2022cited by 14position: lastdoi
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.
2022cited by 7position: contributordoi
Review of: "Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel PD-1+TOX-indifferent Synthetic Effector State"
2022cited by 0position: contributordoi
Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death
International Journal of Pharmaceutics 2021cited by 32position: middledoi
Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
Cancer Prevention Research 2021cited by 18position: middledoi
Persistent STAT5 activation reprograms the epigenetic landscape in CD4 <sup>+</sup> T cells to drive polyfunctionality and antitumor immunity
Science Immunology 2020cited by 84position: lastdoi
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity
Drug Discovery Today 2020cited by 64position: lastdoi
Persistent STAT5 activation reprograms the epigenetic landscape in CD4<sup>+</sup> T cells to drive polyfunctionality and antitumor immunity.
2020cited by 63position: contributordoi
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
MedComm 2020cited by 27position: middledoi
B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets
PLoS ONE 2015cited by 119position: middledoi
Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells
Hepatology 2014cited by 164position: middledoi
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Journal of Clinical Investigation 2013cited by 405position: middledoi
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Journal of Clinical Investigation 2013cited by 309position: middledoi

Grants

CSR: EAGER: A Wearable Body Motion Sensing Platform Using Conductive Stretchable Fabric
NSF1841129$216,0002018–2020PIRePORTER
Quantum Friction, Resonance Problems and New Methods in Geometric Flows
NSF1801387$18,0842017–2018PIRePORTER
TWC: Small: Collaborative: Towards Energy-Efficient Privacy-Preserving Active Authentication of Smartphone Users
NSF1618300$204,3492016–2019PIRePORTER
CAREER: Exploiting Sensing Diversity and Conquering Communication Reality to Meet User Requirements in Performance-Critical Wireless Sensor Networks
NSF1253506$459,1982013–2019PIRePORTER
Quantum Friction, Resonance Problems and New Methods in Geometric Flows
NSF1308985$97,9332013–2014PIRePORTER
Quantum Friction, Resonance Problems and New Methods in Geometric Flows
NSF1443225$83,6662013–2017PIRePORTER
CSR: EAGER: Network Traffic Aware Smartphone Energy Savings
NSF1250180$200,0002012–2015PIRePORTER
NeTS:Small:Collaborative Research:Holistic Transparent Performance Assurance within the Crowded Spectrum
NSF0916994$200,0002009–2012PIRePORTER
Collaborative Research: Multi-Scale QoS for Body Sensor Networks
NSF0901437$175,0002009–2013PIRePORTER

Frequent collaborators

Gary A. Piazza · Auburn University13 papers (2020–2025)Yulia Maxuitenko · Auburn University10 papers (2020–2025)Adam B. Keeton · Washburn University10 papers (2020–2025) · 6 papers (2022–2025) · 6 papers (2020–2025)David H. Munn · University of Sussex5 papers (2020–2025)Khalda Fadlalla · Auburn University5 papers (2023–2025) · 5 papers (2022–2025)Kristy Berry · Auburn University5 papers (2023–2025) · 4 papers (2022–2024)Huidong Shi · Wake Forest University4 papers (2020–2025)Antonio Ward · Mississippi State University3 papers (2020–2023) · 3 papers (2020–2022)Xi Chen · Zhejiang Sci-Tech University3 papers (2020–2025)Xi Chen · Northern Arizona University3 papers (2023–2024)Michael D. Rosenblum · University of California, San Francisco2 papers (2013–2013)Donald J. Buchsbaum · University of Alabama at Birmingham2 papers (2020–2020)Chung-Hui Huang · Auburn University2 papers (2023–2023)Joshua Brody · New York Oncology Hematology2 papers (2013–2013) · 2 papers (2013–2013)